NP wanted a partnership for HIV-1, but Gilead stil

NP wanted a partnership for HIV-1, but Gilead still has time to wait for mono, so CYDY now has no cash to develop the cancers platform on its own. It is risky to wait because the competition is running fast and it is risky to do so with loans. CYDY has the great advantage of receiving Phase II immediately for all indications. The BOD must decide how to put it all together so that development goes forward while maintaining as much value and potential as possible for CYDY. Of course there are interested partners, and I like that NP is so tough in negotiations and only chooses the best partners so we need not doubt that they will choose what's best for CYDY. NP is happy that Leronlimab can act on so many indications so it can choose which indications to partner with or to enter into a big deal.In my opinion we are very close to the turning point which can be, licensing, partnership or merger, BLA, cancers results ... At some point the price can start to rise without any special event because the potentials of all possible indications are huge ...
Many would like CYDY to be able to develop all the indications on their own, but this is impossible for such a small company and rarely can, but few small companies have so many indications and we are in a very good position with Leronlimab. I buy as much as I can before the price goes up... imo